Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics develops targeted protein degradation medicines for immunological diseases as a clinical-stage biopharmaceutical company. News about KYMR commonly centers on oral small molecule degrader programs, including KT-621, a STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and asthma, and KT-579, an IRF5 degrader tied to inflammatory bowel disease biology.
Company updates also cover preclinical and clinical data presentations, FDA regulatory designations, collaboration activity involving degrader candidates such as KT-200, and periodic operating and financial results. Additional announcements include investor conference participation and shareholder voting matters.
Kymera Therapeutics (NASDAQ: KYMR) has announced a PIPE financing, issuing 2,769,228 shares of common stock at $26.00 each and pre-funded warrants for 3,000,000 shares at $25.9999. The anticipated gross proceeds of approximately $150 million will support ongoing R&D and general corporate needs. The financing is led by notable healthcare investors and is expected to close on August 22, 2022. Following the transaction, Kymera's cash reserves are projected to exceed $600 million by August 31, 2022.
Kymera Therapeutics (NASDAQ: KYMR) initiated dosing in Part C of its Phase 1 clinical trial for the IRAK4 degrader KT-474, aiming to share data by year-end 2022. The company has also launched Phase 1 trials for oncology programs KT-333 and KT-413, with results expected soon. As of June 30, 2022, Kymera reported a cash balance of approximately $482.5 million, providing a runway into 2025. Despite an increase in research and development expenses leading to a net loss of $40.3 million for Q2 2022, the company remains on track for significant clinical milestones this year.
Kymera Therapeutics, a clinical-stage biopharmaceutical company, is set to reveal its second quarter 2022 financial results on August 9, 2022. A conference call will follow at 8:30 a.m. ET, accessible via phone or a live webcast on their website. The company focuses on targeted protein degradation, utilizing its Pegasus platform to develop novel therapies for treating various immune-inflammatory diseases and cancers. Founded in 2016 and headquartered in Watertown, Mass., Kymera has gained recognition as an industry leader.
Kymera Therapeutics (NASDAQ: KYMR) announced the appointment of Leigh Morgan to its Board of Directors as of July 8, 2022. Ms. Morgan is recognized for her expertise in building high-performing organizations and will assist Kymera in evolving into a fully-integrated biopharmaceutical company. She has significant experience in human resources and operations, having held key roles at Nia Tero and the Bill & Melinda Gates Foundation. Kymera is advancing targeted protein degradation therapies aimed at treating complex diseases, indicating a strong commitment to innovation in the biopharmaceutical sector.
Kymera Therapeutics (NASDAQ: KYMR) has initiated Phase 1 clinical trials for two first-in-class protein degraders: KT-333, targeting STAT3 for T cell malignancies, and KT-413, targeting IRAK4 for MYD88-mutant B cell lymphomas. The trials aim to assess the safety, tolerability, and pharmacokinetics of these treatments with initial data expected in the second half of 2022. KT-333 has also received Orphan Drug Designation from the FDA, emphasizing its potential in addressing rare diseases.
Kymera Therapeutics (NASDAQ: KYMR) received orphan drug designation from the FDA for KT-333, intended for treating Peripheral T-cell Lymphoma (PTCL). This first-in-class degrader targets STAT3, a protein crucial in PTCL disease modulation. Currently, PTCL lacks approved therapies targeting this pathway. The FDA designation provides development incentives such as tax credits and seven-year marketing exclusivity. KT-333 is in a Phase 1 trial for relapsed/refractory tumors, including aggressive lymphomas, with the potential to transform PTCL treatment.
Kymera Therapeutics (NASDAQ: KYMR) presented new preclinical data at EULAR 2022, showcasing the effectiveness of its investigational STAT3 degraders in blocking Th17 development and cytokine release, thereby preventing collagen-induced arthritis in a mouse model. The research confirms the potential of STAT3 targeting in treating autoimmune disorders, with significant suppression of pro-inflammatory cytokines observed. Kymera's STAT3 degrader, KT-333, currently in Phase 1 trials, is part of a broader strategy to address various immune-inflammatory diseases.
Kymera Therapeutics (NASDAQ: KYMR) presented significant data on its IRAK4 degrader KT-474 at the 2022 Society of Investigative Dermatology Annual Meeting. The findings indicated that KT-474 effectively degrades IRAK4 and inhibits cytokine production across various immune and skin cell types, supporting its potential for treating autoimmune diseases such as hidradenitis suppurativa (HS) and atopic dermatitis (AD). Notably, the Phase 1 clinical study demonstrated nearly complete IRAK4 degradation and cytokine inhibition in healthy volunteers, showcasing the drug's promise in inflammation-related conditions.
Kymera Therapeutics (NASDAQ: KYMR) revealed promising preclinical results at the AAI Annual Meeting 2022, highlighting the effectiveness of their novel protein degraders in treating inflammatory and autoimmune diseases. The data emphasized the advantages of IRAK4 and STAT3 degraders over traditional kinase inhibitors, demonstrating superior inhibition of immune signaling pathways and Th17 inflammation in animal models. These findings support further exploration into using these degraders for therapeutic applications in conditions like multiple sclerosis and rheumatoid arthritis, indicating significant clinical potential.
Kymera Therapeutics (NASDAQ: KYMR) reported key developments in its clinical programs and financial results for Q1 2022. The Phase 1 trial for IRAK4 degrader KT-474 has been amended to extend dosing from 14 to 28 days, allowing for enhanced efficacy evaluation. Clinical trials for STAT3 (KT-333) and IRAKIMiD (KT-413) oncology programs are underway. The company's cash balance stood at approximately $523 million as of March 31, 2022, providing a runway into 2025. Collaboration revenues were $9.6 million, down from $18.7 million in Q1 2021, while net loss increased to $36.7 million.